Skip to main content
Premium Trial:

Request an Annual Quote

Tangen Biosciences Wins $696K BARDA Contract to Develop Point-of-Care Coronavirus MDx Test

NEW YORK ­– Tangen Biosciences has been awarded a $696,000 contract from the Biomedical Advanced Research and Development Authority to develop a point-of-care molecular diagnostic assay for the SARS-CoV-2 virus.

The test would run on Tangen's GeneSpark nucleic acid amplification system and would be sensitive enough for early detection of the virus from nasopharyngeal samples in about an hour. It would also be expected to garner a CLIA waiver for use in doctors' offices.

Upon successful development, Branford, Connecticut-based Tangen is expected to seek Emergency Use Authorization from the US Food and Drug Administration.

Tangen's GeneSpark platform comprises the TangenDx disc and GeneSpark instrument, and performs rotary rapid isothermal nucleic acid amplification and detection. The platform currently features tests for Candida auris, sepsis-causing bacteria, and antibiotic resistance genes, as well as a Candida blood panel.

The company was previously awarded approximately $7 million in two phases from BARDA to develop a point-of-care molecular test for anthrax and a blood-based panel for antibiotic resistance markers.

The Scan

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.

Active Lifestyle Linked to Type 2 Diabetes Prevention in People at High Genetic Risk

A study in the British Journal of Sports Medicine shows that an active lifestyle goes a long way in type 2 diabetes prevention.

Beneficial, Harmful Effects of Introgression Between Wild and Domesticated European Grapes

A paper in PNAS shows that European wild grapevines were an important resource for improving the flavor of cultivated wine grapes.

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.